Literature DB >> 23510919

Statement of the International Working Group on transparency and accountability in drug regulation.

.   

Abstract

Year:  1996        PMID： 23510919     DOI： 10.3233/JRS-1996-9312

Source DB:  PubMed          Journal:  Int J Risk Saf Med        ISSN： 0924-6479


× No keyword cloud information.
  4 in total

Review 1.  Pharmacovigilance in perspective.

Authors:  R H Meyboom; A C Egberts; F W Gribnau; Y A Hekster
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

2.  Transparency in drug regulation: mirage or oasis?

Authors:  Joel Lexchin; Barbara Mintzes
Journal:  CMAJ       Date:  2004-11-23       Impact factor: 8.262

3.  The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour.

Authors:  K Abbasi; A Herxheimer
Journal:  BMJ       Date:  1998-10-03

4.  Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data.

Authors:  Daniel Strech; Jasper Littmann
Journal:  Trials       Date:  2012-07-02       Impact factor: 2.279
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.